Fecal microbiota transplantation as novel therapy in gastroenterology : A systematic review

Visa fullständig post




Rossen , N G , MacDonald , J K , de Vries , E M , D'Haens , G R , de Vos , W M , Zoetendal , E G & Ponsioen , C Y 2015 , ' Fecal microbiota transplantation as novel therapy in gastroenterology : A systematic review ' , World Journal of Gastroenterology , vol. 21 , no. 17 , pp. 5359-5371 . https://doi.org/10.3748/wjg.v21.i17.5359

Titel: Fecal microbiota transplantation as novel therapy in gastroenterology : A systematic review
Författare: Rossen, Noortje G.; MacDonald, John K.; de Vries, Elisabeth M.; D'Haens, Geert R.; de Vos, Willem M.; Zoetendal, Erwin G.; Ponsioen, Cyriel Y.
Upphovmannens organisation: Departments of Faculty of Veterinary Medicine
Willem Meindert Vos de / Principal Investigator
Veterinary Biosciences
Veterinary Microbiology and Epidemiology
Department of Bacteriology and Immunology
de Vos & Salonen group
Datum: 2015-05-07
Språk: eng
Sidantal: 13
Tillhör serie: World Journal of Gastroenterology
ISSN: 1007-9327
DOI: https://doi.org/10.3748/wjg.v21.i17.5359
Permanenta länken (URI): http://hdl.handle.net/10138/163944
Abstrakt: AIM: To study the clinical efficacy and safety of Fecal microbiota transplantation (FMT). We systematically reviewed FMT used as clinical therapy. METHODS: We searched MEDLINE, EMBASE, the Cochrane Library and Conference proceedings from inception to July, 2013. Treatment effect of FMT was calculated as the percentage of patients who achieved clinical improvement per patient category, on an intention-to-treat basis. RESULTS: We included 45 studies; 34 on Clostridium difficile-infection (CDI), 7 on inflammatory bowel disease, 1 on metabolic syndrome, 1 on constipation, 1 on pouchitis and 1 on irritable bowel syndrome (IBS). In CDI 90% resolution of diarrhea in 33 case series (n = 867) was reported, and 94% resolution of diarrhea after repeated FMT in a randomized controlled trial (RCT) (n = 16). In ulcerative colitis (UC) remission rates of 0% to 68% were found (n = 106). In Crohn's disease (CD) (n = 6), no benefit was observed. In IBS, 70% improvement of symptoms was found (n = 13). 100% Reversal of symptoms was observed in constipation (n = 3). In pouchitis, none of the patients (n = 8) achieved remission. One RCT showed significant improvement of insulin sensitivity in metabolic syndrome (n = 10). Serious adverse events were rare. CONCLUSION: FMT is highly effective in CDI, and holds promise in UC. As for CD, chronic constipation, pouchitis and IBS data are too limited to draw conclusions. FMT increases insulin sensitivity in metabolic syndrome.
Subject: Fecal microbiota transplantation
Clostridium difficile infection
Inflammatory bowel disease
Metabolic syndrome
3111 Biomedicine
Referentgranskad: Ja
Licens: cc_by_nc
Användningsbegränsning: openAccess
Parallelpublicerad version: publishedVersion

Filer under denna titel

Totalt antal nerladdningar: Laddar...

Filer Storlek Format Granska
WJG_21_5359.pdf 1.002Mb PDF Granska/Öppna

Detta dokument registreras i samling:

Visa fullständig post